A Pivotal Study of N-Acetyl-L-Leucine on Niemann-Pick Disease Type C
This important study is testing a new medicine called N-Acetyl-L-Leucine (also known as IB1001) for people, aged 4 and older, with Niemann-Pick Disease Type C (NPC). Currently, there isn't a cure for NPC, so finding new treatments is very important. Researchers want to see if this new medicine is safe, well-tolerated, and effective in helping with the condition compared to standard care or a placebo (a dummy treatment with no active medicine). The study is designed in stages, starting with a main study where participants will either receive the new medicine or the placebo. After that, there's a chance to continue with the new medicine for a longer period in an 'extension' part of the study.
Överblick
Vad handlar denna studie om?
If you or someone you know has Niemann-Pick Disease Type C (NPC), you know how challenging it can be. This study is exploring a new potential medicine called N-Acetyl-L-Leucine, also known as IB1001. The main goal is to find out if this medicine is safe and if it can help people aged 4 and older who live with NPC. It's a 'pivotal' study, which means it's a key step in deciding if this new treatment could become widely available in the future. By joining, participants could help contribute to understanding this new medicine better.
The study involves comparing the new medicine with a 'placebo', which looks exactly like the study medicine but doesn't contain any active ingredients. This is a common and important way to test new medicines, as it helps doctors understand if any changes in a person's condition are due to the medicine itself or other factors. Participants won't know if they are receiving the active medicine or the placebo, and neither will their study doctors, which helps keep the results fair and unbiased. Over time, participants in the main study will get to try both the active medicine and the placebo.
After the main part of the study is finished, there's usually an option to continue receiving the new medicine in an 'extension phase'. This extended period allows participants who benefited to continue treatment and helps researchers gather more information about the medicine's long-term effects. This particular extension phase currently offers treatment for up to three years. Participating in a study like this helps researchers learn more about NPC and potentially develop new ways to support people living with the condition.
Viktiga punkter
- This study is testing a new medicine for Niemann-Pick Disease Type C.
- It aims to see if the medicine is safe and helps people aged 4 and older.
- Participants will receive both the new medicine and a 'dummy' treatment (placebo) at different times.
- There's an option to continue receiving the medicine for up to 3 years in an 'extension phase'.
- Participation will help researchers learn more about NPC treatment.
Vem kan vara berättigad?
To be able to join this study, you would need to be aged 4 years or older and have a clear diagnosis of Niemann-Pick Disease Type C, confirmed by genetic tests. If you are a parent or guardian, you'd need to give your permission for your child to take part. For adults capable of making their own decisions, you would need to give your own consent.
For women who might be able to get pregnant, there are specific requirements to make sure you don't become pregnant during the study. This means either agreeing not to have sex during the study period or using very reliable birth control methods. If you are past childbearing age, or have had certain surgical procedures to prevent pregnancy, different rules might apply. Men taking part who are able to father children would also need to use contraception or agree to avoid sex during and after the study for a certain period.
Kan denna studie passa dig?
Svara på dessa snabba frågor för att se om du kan vara berättigad. Detta är endast en vägledning — forskarteamet fattar det slutgiltiga beslutet.
- Are you or your child diagnosed with Niemann-Pick Disease Type C?
- Are you or your child aged 4 years or older?
- If you are a woman who could become pregnant, are you able to avoid pregnancy during the study?
- If you are a man who could father children, are you able to avoid pregnancy during the study?
Vad innebär deltagande?
If you decide to take part, the study will have a few different stages. First, there will be a 'baseline' period of about two weeks where doctors will do checks to understand your health before any study treatment starts. After this, you'll be randomly assigned to either receive the study medicine (N-Acetyl-L-Leucine, or IB1001) or the placebo (dummy treatment) for about 12 weeks. Neither you nor your doctor will know which one you are getting.
Once this first 12 weeks is over, you'll then switch over to receive the opposite treatment – if you had the study medicine, you'll get the placebo, and vice versa – for another 12 weeks. During each of these 12-week periods, you'll have appointments to see the study team who will check how you're doing. After these two treatment periods, there's a chance to join an 'extension phase' where you could receive the active study medicine for up to three years. The total time you'd be involved largely depends on whether you join the extension phase.
Potentiella risker och fördelar
Platser (14)
- Mayo ClinicVerifierat postnummerRochester, USA· Avslutad
- Det Kungliga Melbourne-sjukhusetVerifierat postnummerParkville, Australien· Aktiv men inte rekryterande
- First Faculty of Medicine, Charles University Hospital PragueVerifierat postnummerPrag, Tjeckien· Aktiv men inte rekryterande
- Universitetet i GiessenVerifierat postnummerGiessen, Tyskland· Aktiv men inte rekryterande
- University of HamburgVerifierat postnummerHamburg, Tyskland· Avslutad
- SphinCS - Institute of Clinical Science in Lysosomal Storage DisordersVerifierat postnummerHöchheim, Germany· Aktiv men inte rekryterande
- Ludwig Maximilian University of MunichVerifierat postnummerMünchen, Tyskland· Rekryterar inte ännu
- University Hospital MünsterVerifierat postnummerMünster, Tyskland· Aktiv men inte rekryterande
- Amsterdam UMCVerifierat postnummerAmsterdam, Nederländerna· Rekrytering
- Comenius University in BratislvaVerifierat postnummerBratislava, Slovakia· Aktiv men inte rekryterande
- University Hospital Bern InselspitalVerifierat postnummerBern, Schweiz· Aktiv men inte rekryterande
- Great Ormond Street HospitalVerifierat postnummerLondon, Storbritannien· Aktiv men inte rekryterande
Vanliga frågor
What is Niemann-Pick Disease Type C?
Niemann-Pick Disease Type C is a rare genetic condition that affects the body's ability to move and process certain fats within cells. This can lead to various health problems, including issues with movement, learning, and other bodily functions.
Vad är en 'placebo'?
A placebo is a 'dummy' treatment that looks just like the real medicine but contains no active ingredients. It's used in studies to help doctors understand the true effect of the new medicine.
Kommer jag att veta om jag får den riktiga medicinen eller placebo?
No, during the main part of the study, neither you nor your study doctor will know if you are receiving the active medicine or the placebo. This is called 'double-blind' and helps ensure the study results are fair.
Hur länge kommer studien att pågå?
The main part of the study involves two 12-week treatment periods. After this, you might have the option to join an 'extension phase' where you could receive the active medicine for up to three years.
Kan jag lämna studien när som helst?
Yes, your participation is completely voluntary, and you can withdraw from the study at any point without it affecting your usual medical care.
Hur du får reda på mer
Michael Strupp, MD
Prata alltid med din läkare eller specialist innan du bestämmer dig för att delta i en studie.
Intresserad av att delta?
Diskussion
Gemenskapsdiskussion
Drivs av vårt forum på community.patient.info. Var vänlig och respektfull — detta är inte medicinsk rådgivning.